CF PHARMTECH (02652) has received voluntary extension of the lock-up period on shares held by core management by six months.

CF PHARMTECH (02652) has announced that recently, the Company received voluntary undertakings from Dr. Liang Wenqing, co-founder, Chairman, Executive Director and Chief Executive Officer of the Company, and Dr. Li Li, co-founder, Executive Director and Chief Scientific Officer of the Company, based on their confidence in the Group's long-term development prospects and long-term value. Pursuant to the undertakings, the core management has voluntarily undertaken to further extend the lock-up period on the shares of the Company directly or indirectly beneficially owned by them by six months after the expiry of the original lock-up period. The extended lock-up period shall commence from October 8, 2026 and end on April 7, 2027 (both dates inclusive). The relevant shares refer to: (1) 15,677,400 H shares and 10,451,600 unlisted shares held by Dr. Liang Wenqing through Suzhou Lingtou Investment Management Enterprise (Limited Partnership) controlled by him; (2) 14,378,700 H shares and 9,585,800 unlisted shares held by Dr. Li Li through Suzhou Meizhongrui Investment Management Enterprise (Limited Partnership) controlled by her; and (3) a total of 7,563,300 shares in which Dr. Liang Wenqing and Dr. Li Li respectively have interests through Suzhou Lingtou and Suzhou Meizhongrui in the Company's employee incentive platform (such shares do not belong to the Company's 2024 Share Incentive Scheme). The Company considers that the voluntary undertakings made by the core management are based on their confidence in the Group's long-term development strategy, business prospects and ability to continuously create value, and reflect their commitment to aligning with the long-term interests of the Company and all shareholders. The undertakings were made by the core management on a voluntary and gratuitous basis.